ACC Rockies Chapter Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.


For more information and to register, please visit: ACC Rockies Chapter Meeting 2026



Alina Robert, MD, FACC Chapter President

Robert Duerr, MD, FACC Incoming Governor

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • ACC Urges Changes as Ambulatory Specialty Model Approaches 2027 Launch
    With the mandatory Ambulatory Specialty Model (ASM) for Heart Failure (HF) slated to begin Jan. 1, 2027, the ACC is prioritizing member awareness and education, while pressing the Centers for Medicare and Medicaid Services (CMS) to address key issues with the model's design and requirements.
  • Incorrect Specialty Classifications Identified in ASM Participant List
    An ACC analysis of the preliminary participant list for the Ambulatory Specialty Model (ASM) for Heart Failure found that up to 20% of selected cardiologists may be incorrectly classified under the specialty cardiovascular disease/cardiology.
  • AI-Enabled Clinician: Navigating Large Language Models in Cardiology
    In this episode, Chief Innovation Officer Dr. Ami Bhatt and Dr. Ankeet Bhatt explore the impact of large language models (LLM) on cardiovascular care today.
  • New Research Shows Benefits of Evolocumab, Laroprovstat
    Three new studies published in Circulation highlight advances in lipid-lowering therapy, with early-stage data supporting a first-in-class oral PCSK9 inhibitor and two separate analyses showing that evolocumab reduces major cardiovascular events across a range of high-risk patients, including those with elevated Lp(a) and those with prior PCI but no history of MI.
  • Discontinuation of Antihypertensive Drugs For AEs Vary By Drug Class, Regimen
    A network meta-analysis of the discontinuation of blood-pressure (BP)-lowering medications due to adverse drug effects (AEs) found that the best-tolerated treatment was a combination of an angiotensin receptor blocker (ARB) and calcium channel blocker (CCB), with four of the top five best-tolerated regimens containing ARBs...